

स्वास्थ्य एवं परिवार कल्याण मंत्रालय, भारत सरकार सैक्टर - 23, राज नगर गाजियाबाद - 201 002 (3.प्र.), भारत



INDIAN PHARMACOPOEIA COMMISSION

Ministry of Health & Family Welfare, Government of India Sector-23, Raj Nagar Ghaziabad - 201 002 (U.P.) INDIA

Dated: June 22, 2023

File No. P.17019/01/2018-PvPI

Monthly Drug Safety Alert

The preliminary analysis of Adverse Drug Reactions (ADRs) from the PvPI database revealed that the following suspected drug is associated with the ADR as given below.

Table

S. No.	Suspected Drug	Indication	Adverse Drug Reaction
1	Teneligliptin	For the treatment of Type-2 Diabetes Mellitus as a monotherapy adjunct to diet and exercise.	Bullous Pemphigoid

Healthcare Professionals, Patients/Consumers are advised to closely monitor the possibility of the above ADR associated with the use of above suspected drug. If, such reaction is encountered, please report to the NCC-PvPI, IPC by filling of Suspected Adverse Drug Reactions Reporting Form/Medicines Side Effect Reporting Form for Consumer (http://www.ipc.gov.in), through Android Mobile App "ADR PvPI" and PvPI Helpline No. 1800-180-3024.

Tel. No.: +91-120-2783392, 2783400, 2783401;